Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.

Autor:	Suzuki, Kenshi1 (AUTHOR), Wechalekar, Ashutosh D.2 (AUTHOR), Kim, Kihyun3 (AUTHOR), Shimazaki, Chihiro4 (AUTHOR), Kim, Jin Seok5 (AUTHOR), Ikezoe, Takayuki6 (AUTHOR), Min, Chang-Ki7 (AUTHOR), Zhou, Fude8 (AUTHOR), Cai, Zhen9 (AUTHOR), Chen, Xiaonong10 (AUTHOR), Iida, Shinsuke11 (AUTHOR), Katoh, Nagaaki12 (AUTHOR), Fujisaki, Tomoaki13 (AUTHOR), Shin, Ho-Jin14 (AUTHOR), Tran, NamPhuong15 (AUTHOR), Qin, Xiang16 (AUTHOR), Vasey, Sandra Y.16 (AUTHOR), Tromp, Brenda17 (AUTHOR), Weiss, Brendan M.16 (AUTHOR), Comenzo, Raymond L.18 (AUTHOR)
Zdroj:	Annals of Hematology. Apr2023, Vol. 102 Issue 4, p863-876. 14p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink